Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD. Baselga J, et al. Among authors: lewis phillips gd. Clin Cancer Res. 2016 Aug 1;22(15):3755-63. doi: 10.1158/1078-0432.CCR-15-2499. Epub 2016 Feb 26. Clin Cancer Res. 2016. PMID: 26920887 Free PMC article. Clinical Trial.
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, Du X, Saad O, Bowles K, Olsen S, Lewis Phillips GD, Hartley D, Sliwkowski MX, Girish S, Dambach D, Ramakrishnan V. Uppal H, et al. Among authors: lewis phillips gd. Clin Cancer Res. 2015 Jan 1;21(1):123-33. doi: 10.1158/1078-0432.CCR-14-2093. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370470
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX. Junutula JR, et al. Among authors: lewis phillips gd. Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30. Clin Cancer Res. 2010. PMID: 20805300
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A. Junttila TT, et al. Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16. Cancer Res. 2014. PMID: 25228655
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR. Pillow TH, et al. Among authors: lewis phillips gd. J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18. J Med Chem. 2014. PMID: 25191794
26 results